.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Farmers Insurance
UBS
Cipla
Fish and Richardson
Federal Trade Commission
Covington
Argus Health
Boehringer Ingelheim
Daiichi Sankyo

Generated: November 17, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019627

« Back to Dashboard
NDA 019627 describes DIPRIVAN, which is a drug marketed by Fresenius Kabi Usa and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug. Additional details are available on the DIPRIVAN profile page.

The generic ingredient in DIPRIVAN is propofol. There are twelve drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the propofol profile page.

Summary for 019627

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Pharmacology for NDA: 019627

Physiological EffectGeneral Anesthesia

Medical Subject Heading (MeSH) Categories for 019627

Suppliers and Packaging for NDA: 019627

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DIPRIVAN
propofol
INJECTABLE;INJECTION 019627 NDA RX PHARMA-PACK, INC. 49836-023 49836-023-08 1 KIT in 1 PACKAGE, COMBINATION (49836-023-08) * 50 mL in 1 VIAL, SINGLE-USE * .55 mL in 1 POUCH
DIPRIVAN
propofol
INJECTABLE;INJECTION 019627 NDA RX PHARMA-PACK, INC. 49836-024 49836-024-10 1 KIT in 1 PACKAGE, COMBINATION (49836-024-10) * 20 mL in 1 VIAL * .55 mL in 1 POUCH

Summary for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength10MG/ML
Approval Date:Oct 2, 1989TE:RLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength10MG/ML
Approval Date:Jun 11, 1996TE:ABRLD:Yes
Patent:► SubscribePatent Expiration:Jun 1, 2025Product Flag?Substance Flag?Delist Request?Y

Expired Orange Book Patents for NDA: 019627

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Fresenius Kabi Usa
DIPRIVAN
propofol
INJECTABLE;INJECTION019627-002Jun 11, 1996► Subscribe► Subscribe
Fresenius Kabi Usa
DIPRIVAN
propofol
INJECTABLE;INJECTION019627-002Jun 11, 1996► Subscribe► Subscribe
Fresenius Kabi Usa
DIPRIVAN
propofol
INJECTABLE;INJECTION019627-002Jun 11, 1996► Subscribe► Subscribe
Fresenius Kabi Usa
DIPRIVAN
propofol
INJECTABLE;INJECTION019627-002Jun 11, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Farmers Insurance
Mallinckrodt
Citi
Healthtrust
Julphar
Boehringer Ingelheim
Johnson and Johnson
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot